Kim Paul D, Ludwig Steven, Poelstra Kornelis, Duggan Brian, Scalea Thomas, Gelb Daniel
Department of Orthopaedics, University of Maryland Medical Center, Baltimore, MD 21201, USA.
J Spinal Disord Tech. 2010 May;23(3):215-20. doi: 10.1097/BSD.0b013e31819cc5fb.
Case report.
We report the first described case of ectopic bone formation with osteogenic protein-1 (OP-1) use occurring in the pelvis after combined anterior and posterior spinal fusion.
OP-1 is a member of the transforming growth factor-beta superfamily of extracellular proteins involved in bone growth and formation. Potential side effects of OP-1 are not yet fully understood, and clinical data have failed to show significant adverse effects of OP-1.
The patient had flat-back syndrome with symptomatic junctional degenerative disease below the level of fusion and underwent staged anterior and posterior reconstruction. OP-1 was used in conjunction with local bone graft and crushed cancellous allograft in both anterior and posterior procedures.
Bone grew adjacent to the left superior pubic rami, extending through the left rectus sheath and into the left psoas muscle. Subsequently, complete excision of the ectopic bone was performed. No local recurrence was noted at postoperative visits up to 5 months after excision. At that time, the patient had returned to work and was pleased with the level of function.
Caution is justified with the use of OP-1. Clinical studies must be conducted to ensure appropriate dosing to prevent ectopic bone formation and deleterious effects.
病例报告。
我们报告首例在前后路脊柱融合术后骨盆出现使用成骨蛋白-1(OP-1)导致异位骨形成的病例。
OP-1是参与骨生长和形成的细胞外蛋白转化生长因子-β超家族的成员。OP-1的潜在副作用尚未完全明确,临床数据也未显示OP-1有明显的不良反应。
该患者患有平背综合征,在融合节段以下有症状性交界性退变疾病,接受了分期前后路重建手术。在前路和后路手术中,OP-1均与局部骨移植和碎松质骨同种异体移植联合使用。
异位骨在左耻骨上支附近生长,延伸穿过左腹直肌鞘并进入左腰大肌。随后,对异位骨进行了完整切除。切除术后长达5个月的随访中未发现局部复发。此时,患者已恢复工作,对功能水平感到满意。
使用OP-1时谨慎是合理的。必须进行临床研究以确保适当的剂量,防止异位骨形成和有害影响。